Osteoporosis in Skin Diseases

Area of Science:

• Bone biology and metabolic diseases
• Dermatology and inflammatory conditions
• Public health and epidemiology

Background:

• Osteoporosis (OP) is a major public health issue, characterized by low bone mass and microarchitectural deterioration, increasing fracture risk.
• The global prevalence of OP affects over 200 million people, stemming from an imbalance favoring bone resorption by osteoclasts (OC).
• Chronic inflammation and associated cytokines disrupt the bone remodeling balance, promoting osteoclastogenesis and contributing to bone loss.

Purpose of the Study:

• To review the current understanding of the relationship between osteoporosis and skin diseases.
• To highlight the impact of inflammation and treatments on bone health in dermatological patients.
• To underscore the need for increased attention to bone health in individuals with skin conditions.

Main Methods:

• Literature review of existing studies on osteoporosis and skin diseases.
• Analysis of the role of inflammation and cytokines in both conditions.
• Examination of the effects of dermatological treatments on bone metabolism.

Main Results:

• Inflammation and cytokine patterns are common underlying factors in both osteoporosis and many skin pathologies.
• Dermatological treatments, including glucocorticoids and immunosuppressants, can elevate osteoporosis risk.
• A significant overlap exists between the pathophysiology of skin diseases and bone fragility.

Conclusions:

• There is a strong link between chronic inflammation, skin diseases, and osteoporosis.
• Bone health monitoring is crucial for patients with dermatological conditions, especially those on specific treatments.
• Further research is needed to fully elucidate this under-explored connection and guide clinical practice.